Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1769802 Correction Correction: TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study WuChunxue 1 † Writing – original draft Visualization Software Formal analysis DongYunlong 2 † Writing – original draft Software Data curation Writing – review & editing LiXinge 3 Methodology Investigation Writing – review & editing ShaoWenbo 1 Supervision Writing – review & editing WangGuangshun 2 Resources Writing – review & editing WuHuiyong 1 * Writing – review & editing Data curation Conceptualization Project administration ChangXu 1 * Writing – original draft Visualization Supervision Writing – review & editing Data curation Investigation Validation Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China Department of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China Central Hospital Affiliated to Shandong First Medical University, Jinan, China Correspondence: Huiyong Wu, jinanwhy@163.com; Xu Chang, cx18769785023@163.com

These authors share first authorship

 02 01 2026 2025 16 1769802 17 12 2025 18 12 2025 Copyright © 2026 Wu, Dong, Li, Shao, Wang, Wu and Chang. 2026 Wu, Dong, Li, Shao, Wang, Wu and Chang https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study By Wu C, Dong Y, Li X, Shao W, Wang G, Wu H and Chang X (2025) Front. Immunol. 16:1664756. doi: 10.3389/fimmu.2025.1664756 hepatocellular carcinoma transarterial chemoembolization (TACE) hepatic arterial infusion chemotherapy (HAIC) combination therapy high tumor burden section-at-acceptance Cancer Immunity and Immunotherapy

Affiliation “Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China” was erroneously given as “Shandong Tumor Hospital, Jinan, China”.

Affiliation “Department of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China” was erroneously given as “Tianjin Baodi Hospital, Tianjin, China”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland